Thus, cyclosporine treatments correlated with decreases in the click here rates of adverse effects. Patients with MCNS typically stay for months in hospitals for their treatment. Medical expenses have always been a major issue for long-term hospitalization. There is very limited literature on the costs associated with SRNS

in children and MCNS in adults. Colquitt et al. [23] showed the cost-effectiveness of treatments for children with idiopathic SRNS. The results of the present study suggest that combination therapy with cyclosporine has the advantages of shortening hospitalization and reducing adverse effects. These benefits may contribute to reductions in medical expenses. Our study has some limitations. First, the total number of patients was small in the retrospective study, which could be a source of selection bias. The treatment protocol for Group 1 is the latest treatment option, and we asked this treatment for all patients who met the study criteria. The treatment protocol for Group 2 and Group 3 were freely chosen by

the doctor in charge. However, no significant differences were observed in baseline parameters among the three groups. Thus, selection bias may be minimal. Second, repeated kidney biopsies are required to evaluate renal function ABT-263 manufacturer and adverse effects during long-term treatment. Third, edema in the intestine has been reported in patients with severe nephrotic syndrome, and this may decrease the absorption of drugs, including prednisolone

[24]. Thus, intravenous MPT was adopted as the treatment of choice. As the treatment benefits were limited in the intravenous MPT (Group 2) compared to the prednisolone monotherapy (Group 3) in the present study, we consider combined cyclosporine and oral prednisolone therapy without MPT might be a potential treatment for new-onset MCNS in adults. In conclusion, cyclosporine combined with MPT and oral prednisolone shortened the LOS and decreased the total Molecular motor amount of prednisolone without severe adverse effects when used in patients with the first attack of adult-onset MCNS. Although no significant differences were observed in the days required for complete remission among the three groups, cyclosporine use was associated with the period to complete response in multivariate analysis, and relapse rates were slightly lower in Group 1 than in Group 3. Combination therapy with cyclosporine may be a useful treatment option currently available for new-onset MCNS in adults. Conflict of interest Satoshi Umemura received Honoraria from MSD, Pfizer, Novartis Pharma, Dainippon-Sumitomo. S Umemura received research funding from Daiichi-Sankyou, Nippon Boehringer Ingelheim, Astellas, Novartis Pharma. Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1.